by telrheum | Sep 28, 2024 | Spondyloarthritis, Acute Phase Reactants, Ankylosing Spondylitis, C-reactive Protein, JAK Inhibitor, Tofacitinib
This article presents a post hoc analysis of how baseline (BL) C-Reactive Protein (CRP) levels affect the efficacy and safety of Tofacitinib, a medication used to treat Ankylosing Spondylitis (AS). Tofacitinib is a Janus kinase inhibitor, a type of drug that helps...
by telrheum | Jun 24, 2024 | Biologic Therapy, Anti-TNF, IL-23 Inhibitors, Il-6 inhibitors, JAK Inhibitor, Rituximab
Background: Rheumatoid arthritis (RA) patients often face higher cardiovascular risks due to chronic inflammation. Biologic disease-modifying antirheumatic drugs (biologic drugs) help control this inflammation, especially in those who don’t respond well to...
by telrheum | Jun 16, 2024 | Biologic Therapy, JAK Inhibitor, systemic juvenile idiopathic arthritis
Background: Systemic juvenile idiopathic arthritis (sJIA) is a severe form of arthritis in children that can lead to serious complications like macrophage activation syndrome (MAS) and lung disease. Even with current treatments like steroids and IL-1 inhibitors, some...
by telrheum | May 27, 2024 | Autoimmune Diseases, Biologic Therapy, IgG4-Related Diseases, JAK Inhibitor
The article “Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients” presents a study conducted at Peking University People’s Hospital. The study aimed to evaluate the effectiveness and safety of tofacitinib, a Janus...
by telrheum | May 25, 2024 | Interstitial Lung Disease, JAK Inhibitor, Systemic Sclerosis
This study explored the effectiveness and safety of nintedanib (NTB), a drug approved for progressive fibrosing interstitial lung disease (PF-ILD), in combination with immunosuppressive agents (IS) for treating connective tissue disease-associated PF-ILD (CTD-PF-ILD)....
by telrheum | May 19, 2024 | Il-6 inhibitors, Hepatitis B, Infections, JAK Inhibitor
This study, presented at ACR Convergence 2023 by Akhil Sood, Janice Lin, and Neha Shah from Stanford University, examines the risk of Hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) who are being treated with either JAK inhibitors or...
